The TM20 Device
Our proprietary methodology includes the use of the patented Moore MyoWorx TM20 device.
Safe and Effective
The TM20 device is approved by the FDA to be a safe and effective treatment for muscle relaxation and increased local blood flow. The MyoWorx TM20 device can precisely target distressed areas to deliver a specified sequence of timed and abrupt electrical frequency changes.
The frequencies used in the MyoWorx TM20 treatment decrease the tension of the muscle fibers and lead to greater blood flow inducing biochemical changes affecting the fatigued or injured muscles.
By altering the biochemical changes that occur in these muscles, the treatment restores proper long-term control of blood flow to the muscle. This enables the muscles to completely relax and prepares them for the next phase of treatment, accelerating the positive impact of our specifically designed exercises and healing.
Revolutionizing Healing
Our two Moore MyoWorx clinics, in Canada and Colorado are the only two clinics in the world to offer targeted muscle relaxation to accelerate healing using our internationally acclaimed, evidence-based model.
Moore MyoWorx goes beyond symptom management to heal the underlying injury itself. Developed by Terry Moore, Moore MyoWorx treatment enables the patient to take back control of their life through specifically designed exercise facilitated by the MyoWorx TM20.
It is a comprehensive approach that includes all phases of treatment – from a comprehensive initial assessment to in-clinic treatment and at-home participation.
Empowering Recovery
The World Health Organization has estimated that mild traumatic brain injury affects more than 6/1000 people a year.
In order to garner a better understanding of dizziness in TBI and effective treatment for TBI-related dizziness, we published research on before and after therapy and treatment. As such, findings offer additional support for the use of soft tissue release, specialized electrotherapy, and exercise in the treatment of dizziness related to TBI.